Wednesday, 23 June 2010
AstraZeneca and Targacept, Inc., today announced the enrolment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker. The Phase 3 program, referred to as the Renaissance Program, is designed to support the planned second half of 2012 filing of a new drug application with the U.S. Food and Drug Administration for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norephinephrine reuptake inhibitor (SNRI). A Marketing Authorisation Application in Europe is planned for 2014.
AstraZeneca and Targacept have designed the Renaissance Program to include two fixed dose Phase 3 studies and two flexible dose Phase 3 studies to evaluate the efficacy and tolerability of TC-5214 as an adjunct treatment in patients with an inadequate response to SSRI or SNRI therapy. The Renaissance Program also includes a double blind, placebo controlled long-term safety study in which patients would receive TC-5214 or placebo for up to one year. All studies in the Renaissance Program are on track to initiate this year.
Each of the fixed dose and flexible dose Phase 3 studies includes an open label first phase in which patients diagnosed with MDD receive one of seven marketed SSRIs or SNRIs for eight weeks to determine the extent of therapeutic response. For each study, patients who do not respond adequately based on predefined criteria are to be randomized into a double blind, placebo controlled second phase to receive a fixed dose (in the case of the fixed dose trials) or a flexible dose that may escalate (in the case of the flexible dose trials) of TC-5214 or placebo, twice daily, while continuing the SSRI or SNRI therapy for an additional eight weeks. The primary outcome measure for each study is change from double blind baseline for TC-5214 on the Montgomery-Asberg Depression Rating Scale (MADRS) as compared to placebo.
NOTES TO EDITORS:
About TC-5214
Recent scientific evidence suggests that depressive symptoms are
associated with an overstimulation of neuronal nicotinic receptors
(NNRs) and other receptors in the brain that are activated by the
neurotransmitter acetylcholine. This overstimulation is referred to as
increased cholinergic tone. TC-5214 blocks certain NNR channels, which
is believed to help normalize cholinergic tone resulting in
antidepressant effects.
In 2009, Targacept completed a double blind, placebo controlled Phase 2b clinical trial of TC-5214 as an adjunct treatment in patients with MDD who did not respond adequately to first line therapy with the SSRI citalopram. In this study, TC-5214 outperformed placebo on the primary outcome measure (Hamilton Rating Scale for Depression-17) and all secondary outcome measures with statistical significance.
About the Collaboration Agreement between AstraZeneca and Targacept
In December 2009, AstraZeneca and Targacept signed a collaboration and
license agreement for the global development and commercialization of
TC-5214. The initial goal for the collaboration is to develop TC-5214
as an adjunct treatment for MDD in patients with an inadequate response
to an SSRI or SNRI to regulatory approval. A Phase 2 clinical study to
assess TC-5214 as a second line (“switch”) monotherapy treatment for MDD
is targeted to start in 2010.
About Major Depressive Disorder
MDD is a common illness, affecting approximately 42 million people
worldwide, and the global antidepressant market is estimated to be
approximately $20 billion. SSRIs and SNRIs are the most commonly
prescribed classes of drugs for depression, but in many cases patients
fail to respond adequately. In the NIMH’s large-scale STAR*D study
approximately 63% of patients did not achieve remission with first-line
treatment with the SSRI citalopram hydrobromide.
About Targacept
Targacept is developing a diverse pipeline of innovative NNR
Therapeutics™ for difficult-to-treat diseases and disorders of the
nervous system. NNR Therapeutics selectively modulate the activity of
specific neuronal nicotinic receptors, a unique class of proteins that
regulate vital biological functions that are impaired in various disease
states. Targacept’s lead program, TC-5214, is in Phase 3 development
as an adjunct treatment for major depressive disorder. Targacept
leverages its scientific leadership and proprietary drug discovery
platform Pentad™ to generate novel small molecule product candidates to
fuel its pipeline, and uses its expertise to create significant
alliances with global pharmaceutical companies. Targacept is committed
to Building Health and Restoring Independence™ for patients. For more
information, please visit www.targacept.com.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business
with a primary focus on the discovery, development and commercialisation
of prescription medicines. As a leader in gastrointestinal,
cardiovascular, neuroscience, respiratory and inflammation, oncology and
infectious disease medicines, AstraZeneca generated global revenues of
US $32.8 billion in 2009. For more information please visit:
www.astrazeneca.com.
CONTACTS:
Media Enquiries:
Neil McCrae +44 20 7304 5045 (24 hours)
Chris Sampson +44 20 7304 5130 (24 hours)
Sarah Lindgreen +44 20 7304 5033 (24 hours)
Abigail Baron +44 20 7304 5034 (24 hours)
Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Karl Hård +44 207 304 5322 mob: +44 7789 654364
Clive Morris +44 207 304 5084 mob: +44 7710 031012
Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043